



Biocon Limited

20th KM, Hosur Road

Electronic City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/142

December 17, 2025

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Press Release

Please find enclosed the press release titled “**Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM**”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Press Release

Press Release

Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM

Bengaluru, Karnataka, India: December 17, 2025:

Biocon Biologics Limited, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), announced today that it has been recognized as an **Asia IP Elite** for **2025** by IAM (Intellectual Asset Management), the world's leading Intellectual Property (IP) publication.

This prestigious accolade is awarded to a select group of Asia-based organizations that have demonstrated exceptional IP value creation and are considered leaders in the region. The award was presented during IPBC Asia, held in Tokyo from November 18–20, 2025.

Biocon first earned its place on the Asia IP Elite list in 2016, becoming the first and only Indian pharmaceutical company to be featured for its robust IP management and consistent IP value creation. In subsequent years, Biocon Biologics has continued this legacy, with the two entities together being among the few Indian pharmaceutical companies consistently featured on the Asia IP Elite roster. The 2025 recognition marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: *“Our inclusion in the Asia IP Elite list for 2025 marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list. This reflects our sustained commitment to innovation and strong intellectual property strategy. It reinforces our growing stature as a global biosimilars leader and the role of our IP strategy in expanding access to high-quality, affordable therapies for patients worldwide.”*

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite.

About IAM

Intellectual Asset Management (IAM) is a bimonthly magazine published by Globe White Page, which provides worldwide insight and expertise on managing intellectual property as a key business asset. Its suite of tools, intelligence, legal know-how and data empowers companies to mitigate risks, optimize operations, spot new commercial opportunities and maximize the value of patent, trade secret and other IP assets. www.iam-media.com

About Biocon Biologics Limited

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve over 6.3 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-

communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). **Website:** www.bioconbiologics.com; **Follow us on X (formerly Twitter):** @BioconBiologics and **LinkedIn:** [Biocon Biologics](#) for company updates.

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on **X (formerly Twitter)** @bioconlimited and **LinkedIn:** @BioconLimited for company updates. For FY25 Integrated Annual Report of Biocon [click here](#)

FOR MORE INFORMATION	
MEDIA	INVESTORS
Rumman Ahmed Senior Director, Biocon Biologics +91 9845104173 rumman.ahmed@biocon.com Lance Longwell Public Relations Lead – Advanced Markets, Biocon Biologics +1 857 270 4391 lance.longwell@biocon.com	Prashant Nair Head – Investor Relations, Biocon Biologics +91 98200 95476 prashant.nair@biocon.com